157 related articles for article (PubMed ID: 25249292)
21. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
22. Trichomegaly Induced by Cetuximab: Case Series and Review the Literature.
Koksal UI; Pilanci KN; Ordu C; Okutur K; Saglam S; Demir G
Am J Ther; 2016; 23(5):e1226-9. PubMed ID: 26079631
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Ong CK; Tan WC; Chan LC; Abdul Razak M
Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
[TBL] [Abstract][Full Text] [Related]
24. A case of bullous dermatitis induced by erlotinib.
Oteri A; Cattaneo MT; Filipazzi V; Ferrario S; Gambaro A; Isabella L; Tosca N; Clementi E; Radice S; Piazza E
Oncologist; 2009 Dec; 14(12):1201-4. PubMed ID: 19965913
[TBL] [Abstract][Full Text] [Related]
25. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody).
Foerster CG; Cursiefen C; Kruse FE
Cornea; 2008 Jun; 27(5):612-4. PubMed ID: 18520515
[TBL] [Abstract][Full Text] [Related]
26. Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review.
Zheng H; Zhang H; Zhang T; Wang Q; Hu F; Li B
Exp Ther Med; 2016 Sep; 12(3):1287-1292. PubMed ID: 27588051
[TBL] [Abstract][Full Text] [Related]
27. Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.
Bétrian S; Gomez-Roca C; Vigarios E; Delord JP; Sibaud V
JAMA Dermatol; 2017 Jul; 153(7):723-725. PubMed ID: 28538953
[No Abstract] [Full Text] [Related]
28. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
30. Trichomegaly of eyelashes after treatment with erlotinib in carcinoma pancreas.
Goel V; Raina S; Chandragouda D; Singh S; Talwar V; Patnaik N
Int J Trichology; 2014 Jan; 6(1):23-4. PubMed ID: 25114450
[TBL] [Abstract][Full Text] [Related]
31. Acquired trichomegaly of the eyelashes and hypertrichosis induced by bimatoprost.
Herane MI; Urbina F
J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):644-5. PubMed ID: 15324422
[No Abstract] [Full Text] [Related]
32. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K
Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
[TBL] [Abstract][Full Text] [Related]
33. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
34. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.
Chou CL; Ko HW; Wang CW; Yu CT; Kuo HP; Huang CD
Chang Gung Med J; 2010; 33(1):100-5. PubMed ID: 20184801
[TBL] [Abstract][Full Text] [Related]
36. Erlotinib induced target-like purpura.
Rungtrakulchai R; Rerknimitr P
Dermatol Online J; 2014 Feb; 20(2):. PubMed ID: 24612572
[TBL] [Abstract][Full Text] [Related]
37. Erlotinib-induced scalp perifolliculitis.
Rallis E; Petronic-Rosic V; Korfitis C
Skinmed; 2012; 10(2):70-1. PubMed ID: 22545319
[TBL] [Abstract][Full Text] [Related]
38. Persistent corneal epithelial defect associated with erlotinib treatment.
Johnson KS; Levin F; Chu DS
Cornea; 2009 Jul; 28(6):706-7. PubMed ID: 19512896
[TBL] [Abstract][Full Text] [Related]
39. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.
Saint-Jean A; Sainz de la Maza M; Morral M; Torras J; Quintana R; Molina JJ; Molina-Prat N
Ophthalmology; 2012 Sep; 119(9):1798-802. PubMed ID: 22584020
[TBL] [Abstract][Full Text] [Related]
40. [Hemolytic anemia under erlotinib treatment].
Sakhri L; Mennecier B; Quoix A
Rev Pneumol Clin; 2013 Dec; 69(6):345-50. PubMed ID: 24183296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
